Pharmacokinetic-guided Dosing of Emicizumab
מצבים רפואיים
Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe · Adolescent · Child · Adult
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
Saskia Schols, Dr, MD (Sub-investigator)Maastricht University Medical Center, Maastricht, Limburg, Netherlands
Floor Moenen, Dr, MD (Sub-investigator)Amsterdam University Medical Center, Amsterdam, North Holland, Netherlands
Contact: Study coordinator (Michiel Coppens, Dr, MD) · m.coppens@amsterdamumc.nl · +31(0)20 566 5964Michiel Coppens, Dr, MD (Sub-investigator)Leids Universitair Medisch Centrum, Leiden, South Holland, Netherlands
Paul den Exter, Dr, MD (Sub-investigator)Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Marjon Cnossen, Dr. MD (Sub-investigator)HagaZiekenhuis, The Hague, South Holland, Netherlands
Paula Ypma, MD (Sub-investigator)University Medical Center Groningen, Groningen, Netherlands
Louise Hooimeijer, MD (Sub-investigator)University Medical Center Utrecht, Utrecht, Netherlands
Contact: Principal Investigator (Kathelijn Fischer, Dr, MD)Konrad van der Zwet, MD (Sub-investigator)Lize F.D. van Vulpen, Dr, MD (Sub-investigator)Roger E.G. Schutgens, Prof, MD (Sub-investigator)Paul van der Valk, MD (Sub-investigator)Karin P.M. van Galen, Dr, MD (Sub-investigator)Nanda Uitslager, Msc (Sub-investigator)
מובילי המחקר
Study Officials Fischer, Dr, MD
Principal Investigator
UMC Utrecht